Nasdaq · CIK 0001593899
AVIR Atea Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Mar 13, 2026. Close $5.15 on Oct 9, 2026, +74% from the 52-week low and -16% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
AVIROct 9, 2026 · close 5.15
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Atea Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Franklin M Berger director buy | $81k 25,000 shares | +6% | - | |
| 50Moderate | Franklin M Berger director sell | $1.0M 359,606 shares | -44% | - |
Transactions
The last 98 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Andrea Corcoran See Remarks | MOption exercise Common Stock | +60,000 | $1.24 | $74k | 823,576 | Mar 13, 2026 |
| Mar 11, 2026 | Andrea Corcoran See Remarks | MOption exercise Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 0 | Mar 13, 2026 |
| Jan 31, 2026 | Wayne Foster EVP, Chief Accounting Officer | MOption exercise Common Stock | +41,333 | - | - | 91,461 | Feb 3, 2026 |
| Jan 31, 2026 | Maria Arantxa Horga Chief Medical Officer | MOption exercise Common Stock | +51,283 | - | - | 112,159 | Feb 3, 2026 |
| Jan 31, 2026 | John Vavricka Chief Commercial Officer | MOption exercise Common Stock | +42,083 | - | - | 94,164 | Feb 3, 2026 |
| Jan 31, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Common Stock | +272,983 | - | - | 573,923 | Feb 3, 2026 |
| Jan 31, 2026 | Andrea Corcoran See Remarks | MOption exercise Common Stock | +54,866 | - | - | 779,680 | Feb 3, 2026 |
| Jan 31, 2026 | Janet MJ Hammond Chief Development Officer | MOption exercise Common Stock | +58,050 | - | - | 141,801 | Feb 3, 2026 |
| Jan 31, 2026 | Maria Arantxa Horga Chief Medical Officer | FTax withholding Common Stock | -16,073 | $4.24 | $68k | 96,086 | Feb 3, 2026 |
| Jan 31, 2026 | Wayne Foster EVP, Chief Accounting Officer | FTax withholding Common Stock | -12,132 | $4.24 | $51k | 79,329 | Feb 3, 2026 |
| Jan 31, 2026 | John Vavricka Chief Commercial Officer | FTax withholding Common Stock | -11,570 | $4.24 | $49k | 82,594 | Feb 3, 2026 |
| Jan 31, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | FTax withholding Common Stock | -106,093 | $4.24 | $450k | 467,830 | Feb 3, 2026 |
| Jan 31, 2026 | Janet MJ Hammond Chief Development Officer | FTax withholding Common Stock | -14,136 | $4.24 | $60k | 127,665 | Feb 3, 2026 |
| Jan 31, 2026 | Andrea Corcoran See Remarks | FTax withholding Common Stock | -16,104 | $4.24 | $68k | 763,576 | Feb 3, 2026 |
| Jan 31, 2026 | Maria Arantxa Horga Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -41,533 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Janet MJ Hammond Chief Development Officer | MOption exercise Restricted Stock Unitsderivative | -46,800 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Andrea Corcoran See Remarks | MOption exercise Restricted Stock Unitsderivative | -44,366 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Wayne Foster EVP, Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Feb 3, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Common Stock | +300,000 | $1.24 | $372k | 767,830 | Feb 3, 2026 |
| Jan 31, 2026 | Andrea Corcoran See Remarks | MOption exercise Restricted Stock Unitsderivative | -10,500 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Janet MJ Hammond Chief Development Officer | MOption exercise Restricted Stock Unitsderivative | -11,250 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Wayne Foster EVP, Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -8,000 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | John Vavricka Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Maria Arantxa Horga Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -9,750 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Andrea Corcoran See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Feb 3, 2026 |
| Jan 31, 2026 | Maria Arantxa Horga Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +173,500 | $0.00 | $0 | 173,500 | Feb 3, 2026 |
| Jan 31, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Restricted Stock Unitsderivative | -173,466 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | Janet MJ Hammond Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +177,000 | $0.00 | $0 | 177,000 | Feb 3, 2026 |
| Jan 31, 2026 | Wayne Foster EVP, Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +108,000 | $0.00 | $0 | 108,000 | Feb 3, 2026 |
| Jan 31, 2026 | John Vavricka Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -8,750 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | John Vavricka Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +119,520 | $0.00 | $0 | 119,520 | Feb 3, 2026 |
| Jan 31, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Restricted Stock Unitsderivative | -99,517 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Feb 3, 2026 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jun 20, 2025 | Barbara Gayle Duncan director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 62,750 | Jun 24, 2025 |
| Jun 20, 2025 | Polly A. Murphy director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 86,045 | Jun 24, 2025 |
| Jun 20, 2025 | Franklin M Berger director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 506,497 | Jun 24, 2025 |
| Jun 20, 2025 | Bruce Polsky director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 95,206 | Jun 24, 2025 |
| Jun 20, 2025 | Bruno Lucidi director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 112,750 | Jun 24, 2025 |
| Jun 20, 2025 | Howard Berman director | AGrant or award Stock Option (Right to Buy)derivative | +164,800 | $0.00 | $0 | 164,800 | Jun 24, 2025 |
| Jun 20, 2025 | Jerome M. Adams director | MOption exercise Common Stock | +29,600 | $0.00 | $0 | 62,750 | Jun 24, 2025 |
| Jun 20, 2025 | Bruno Lucidi director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Bruce Polsky director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Barbara Gayle Duncan director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Franklin M Berger director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Jerome M. Adams director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Polly A. Murphy director | AGrant or award Restricted Stock Unitsderivative | +29,600 | $0.00 | $0 | 29,600 | Jun 24, 2025 |
| Jun 20, 2025 | Bruno Lucidi director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Barbara Gayle Duncan director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Bruce Polsky director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Jerome M. Adams director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Franklin M Berger director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Polly A. Murphy director | AGrant or award Stock Option (Right to Buy)derivative | +41,200 | $0.00 | $0 | 41,200 | Jun 24, 2025 |
| Jun 20, 2025 | Barbara Gayle Duncan director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | Franklin M Berger director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | Bruce Polsky director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | Bruno Lucidi director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | Jerome M. Adams director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | Polly A. Murphy director | MOption exercise Restricted Stock Unitsderivative | -29,600 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Feb 20, 2025 | Arthur S Kirsch director | AGrant or award Stock Option (Right to Buy)derivative | +164,800 | $0.00 | $0 | 164,800 | Feb 24, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | MOption exercise Common Stock | +46,800 | - | - | 84,272 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | MOption exercise Common Stock | +33,333 | - | - | 54,848 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | MOption exercise Common Stock | +41,533 | - | - | 67,197 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | MOption exercise Common Stock | +44,367 | - | - | 722,909 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Common Stock | +173,467 | - | - | 290,024 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | MOption exercise Common Stock | +33,333 | - | - | 54,190 | Feb 4, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | AGrant or award Common Stock | +11,250 | - | - | 95,522 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | AGrant or award Common Stock | +99,517 | - | - | 389,541 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | AGrant or award Common Stock | +9,750 | - | - | 76,947 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | AGrant or award Common Stock | +8,000 | - | - | 62,190 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | AGrant or award Common Stock | +10,500 | - | - | 733,409 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | AGrant or award Common Stock | +8,750 | - | - | 63,598 | Feb 4, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | FTax withholding Common Stock | -14,134 | $3.06 | $43k | 81,388 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | FTax withholding Common Stock | -16,071 | $3.06 | $49k | 60,876 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | FTax withholding Common Stock | -12,062 | $3.06 | $37k | 50,128 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | FTax withholding Common Stock | -16,102 | $3.06 | $49k | 717,307 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | FTax withholding Common Stock | -11,517 | $3.06 | $35k | 52,081 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | FTax withholding Common Stock | -88,601 | $3.06 | $271k | 300,940 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | MOption exercise Restricted Stock Unitsderivative | -44,367 | $0.00 | $0 | 44,366 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 33,333 | Feb 4, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | MOption exercise Restricted Stock Unitsderivative | -46,800 | $0.00 | $0 | 46,800 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -41,533 | $0.00 | $0 | 41,533 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -33,333 | $0.00 | $0 | 33,333 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | AGrant or award Restricted Stock Unitsderivative | +8,000 | $0.00 | $0 | 8,000 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +9,750 | $0.00 | $0 | 9,750 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | AGrant or award Restricted Stock Unitsderivative | +10,500 | $0.00 | $0 | 10,500 | Feb 4, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | AGrant or award Restricted Stock Unitsderivative | +11,250 | $0.00 | $0 | 11,250 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | MOption exercise Restricted Stock Unitsderivative | -173,467 | $0.00 | $0 | 173,466 | Feb 4, 2025 |
| Jan 31, 2025 | Janet MJ Hammond Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 4, 2025 |
| Jan 31, 2025 | Andrea Corcoran See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +8,750 | $0.00 | $0 | 8,750 | Feb 4, 2025 |
| Jan 31, 2025 | Maria Arantxa Horga Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +192,800 | $0.00 | $0 | 192,800 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | AGrant or award Restricted Stock Unitsderivative | +99,518 | $0.00 | $0 | 99,518 | Feb 4, 2025 |
| Jan 31, 2025 | Wayne Foster EVP, Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,100 | $0.00 | $0 | 120,100 | Feb 4, 2025 |
| Jan 31, 2025 | John Vavricka Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +132,800 | $0.00 | $0 | 132,800 | Feb 4, 2025 |
| Jan 31, 2025 | Jean-Pierre Sommadossi President, CEO, and Chairman | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Feb 4, 2025 |
| Jan 15, 2025 | Franklin M Berger director | POpen-market purchase Common Stock | -15,000 | $3.19 | $48k | 466,897 | Jan 17, 2025 |
| Jan 16, 2025 | Franklin M Berger director | POpen-market purchase Common Stock | -10,000 | $3.36 | $34k | 476,897 | Jan 17, 2025 |
| Dec 10, 2024 | Franklin M Berger director | SOpen-market sale Common Stock | -359,606 | $2.85 | $1.0M | 451,897 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jerome M. Adamsdirector
- Franklin M Bergerdirector
- Howard Bermandirector, chair, officer
- Andrea CorcoranSee Remarks
- Barbara Gayle Duncandirector
- Wayne FosterEVP, Chief Accounting Officer
- Janet MJ HammondChief Development Officer
- Maria Arantxa HorgaChief Medical Officer
- Arthur S Kirschdirector
- Bruno Lucididirector
- Polly A. Murphydirector
- Bruce Polskydirector
- Jean-Pierre SommadossiPresident, CEO, and Chairman
- John VavrickaChief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.